The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing “extremely ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...